Citi downgraded both AbbVie (NYSE:ABBV) and Merck (NSE:PROR) to Neutral in separate notes Wednesday, citing long-term growth concerns and late-stage pipeline limitations as headwinds for the ...

The report provides extensive insights into over 180 companies and 200 drugs in the PD-1 and PD-L1 inhibitors market. This comprehensive resource focuses on treatment assessments by product type, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

On May 12th the president signed an executive order that seeks to force drugmakers to reduce their prices in America to align ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for ...

IF THERE’S one thing every American agrees on, it’s that politics has become vicious. There are plenty of explanations for ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

Trump signed a similar executive order in the final weeks of his first term, but a court order later blocked the rule from ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

President Donald Trump has issued a new executive order giving pharmaceutical companies a 30-day window to voluntarily lower ...